Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Mi
Palvella Therapeutics submits first module of rolling NDA to FDA for QTORIN 3.9% rapamycin anhydrous gel approval